Atrial Fibrillation
Conditions
Brief summary
The main objective of the study is to assess preferences of Non Valvular Atrial Fibrillation (NVAF) patients towards different options of an anticoagulation treatment. Patient preferences for anticoagulant treatment attributes (convenience attributes only), based on a Discrete Choice Experiment(DCE) interview will be elicited and the impact of switching from Vitamin K Antagonist(VKA) to Xarelto® on Atrial Fibrilation(AF) patient treatment satisfaction will be documented, measured by score differences of the Anti-Clot Treatment Scale (ACTS) score in patients switching from VKA to Rivaroxaban.
Interventions
No specified dosing or dosage in the study. The treatment decision falls within current practice and the prescription of the medicines is clearly separated from the decision to include the patient in the study.
Sponsors
Janssen Research & Development, LLC
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female and male patients ≥ 20 years of age (legal age limit in Taiwan) with a confirmed diagnosis of AF (non-valvular). * Treatment with VKA for at least 6 weeks. * Decision to initiate treatment with Rivaroxaban has been made as per investigator's routine treatment practice. * Written informed consent of the patient. * Wilingness and capability to conduct two F2F interviews.
Exclusion criteria
* Contraindications to the use of Rivaroxaban as outlined in the local product information . * Concomitant treatment with any other anticoagulants. * Participation in another study (clinical intervention/observational) within the 3 months prior to enrollment. * Patients participating in an investigational program with interventions outside of routine clinical practice.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient preferences for anticoagulant treatment attributes (utility values obtained in Logit/Probit estimates) | At 3 months | The preferred attributes will be assessed by a questionnaire following a discrete choice experimental design. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of the Anti-clot treatment scale (ACTS) benefit and burden score from baseline (on VKA) to 3 months (on Xarelto) | At 0 month and at 3 months | ACTS = Anti Clot treatment Scale is a questionnaire of 17 items (13 items on burden of treatment and 4 items on the benefits of treatment) |
| AF symptoms as measured by European Heart Rhythm Association (EHRA) symtoms (both severity and frequency) | At 3 months | — |
| Reasons for switch from VKA to Xarelto | At 0 month | The reasons are selected by the participant out of a qualitative list of reasons for switch from VKA to Xarelto. |
Countries
Taiwan
Outcome results
None listed